Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01994486 · ClinicalTrials.gov registry record · Phase 2
Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01994486 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 20 participants.
The verdict
NCT01994486, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label, multi center study of treatment-naive non-cirrhotic subjects with genotype 1 chronic Hepatitis C Virus. All subjects will receive telaprevir (TVR) in combination with sofosbuvir (SOF) for 12 weeks.
Interventions
- DRUG Telaprevir and Sofosbuvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01994486
The ClinicalTrials.gov registry entry for NCT01994486 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Telaprevir and Sofosbuvir is the first listed.
NCT01994486 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01994486 about?
NCT01994486 is a clinical study titled "Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1". This is an open-label, multi center study of treatment-naive non-cirrhotic subjects with genotype 1 chronic Hepatitis C Virus. All subjects will receive telaprevir (TVR) in combination with sofosbuvir (SOF) for 12 weeks.
What is the current status of trial NCT01994486?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-12. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01994486?
The interventions under investigation include: Telaprevir and Sofosbuvir (DRUG).
Who is sponsoring clinical trial NCT01994486?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.